Last generation instrument for agriculture multispectral data collection

In recent years, the acquisition and analysis of multispectral data are gaining a growing interest and importance in agriculture. On the other hand, new technologies are opening up for the possibility of developing and implementing sensors with relatively small size and featuring high technical performances. Thanks to low weights and high signal to noise ratios, such sensors can be transported by different type of means (terrestrial as well as aerial vehicles), giving new opportunities for assessment and monitoring of several crops at different growing stages or health conditions. The choice and specialization of individual bands within the electromagnetic spectrum ranging from the ultraviolet to the infrared, plays a fundamental role in the definition of the so-called vegetation indices (eg. NDVI, GNDVI, SAVI, and dozens of others), posing new questions and challenges in their effective implementation. The present paper firstly discusses the needs of low-distance based sensors for indices calculation, then focuses on development of a new multispectral instrument specially developed for agricultural multispectral analysis. Such instrument features high frequency and high resolution imaging through nine different sensors (1 RGB and 8 monochromes with relative band-pass filters, covering the 390 to 950 nm range). The instrument allows synchronized multiband imaging thanks to integrated global shutter technology, with a frame rate up to 5 Hz; exposure time can be as low as 1/5000 s. An applicative case study is eventually reported on an area featuring different materials (organic and non-organic), to show the new instrument potential. Last generation instrument for agriculture multispectral data collection. Available from: https://www.researchgate.net/publication/317596952_Last_generation_instrument_for_agriculture_multispectral_data_collection [accessed Jul 11, 2017]

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

open7siBackground The development of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) has improved the survival outcomes of patients with advanced ALK-rearranged non-small-cell lung cancer (NSCLC). The adverse events (AEs) related to ALK inhibitors are fairly well known; notably, about 20% of patients receiving lorlatinib experienced cognitive effects and behavioral alterations in pivotal trials. Therefore, psychiatric disorders could represent AEs of special interest for all ALK TKIs, deserving careful assessment in the post-marketing setting. Objective We conducted a real-world pharmacovigilance study on psychiatric AEs with marketed ALK inhibitors in subjects with advanced NSCLC. Patients and methods We performed an observational, retrospective analysis of spontaneous reports submitted to the Food and Drug Administration Adverse Events Reporting System (FAERS, as of December 2020), selecting psychiatric AEs to ALK TKIs approved in NSCLC (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib). These AEs were independently scrutinized by three oncologists applying predefined exclusion criteria, described in terms of clinical/demographic features and assessed for drug-related causality according to an adaptation of the WHO–UMC system, a standardized probabilistic algorithm. Results Among 584 reported psychiatric AEs, 95 cases were selected as potentially treatment related, with higher reporting frequency for lorlatinib (26, 2.8%), followed by brigatinib (10, 1.2%), alectinib (18, 0.7%), ceritinib (12, 0.6%), and crizo- tinib (29, 0.3%). Reported psychiatric symptoms were mood disorders (39), psychotic disorders (24), and anxiety, agitation, and irritability (25). In the majority (74%) of cases, psychiatric AEs were serious and required hospitalization in about 32% of patients; 15.8% of retained cases were considered as highly probable and 69.5% as probable. Drug discontinuation was recorded in 31.6% of the reported cases, with the highest proportion for lorlatinib (65.4%). Conclusion Notwithstanding limitations, our study found a higher proportion of psychiatric AEs with lorlatinib, but also raised the hypothesis of psychiatric reactions as a class effect of ALK TKIs.openSisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, FrancescoSisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesc

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment and care of patients with cancer owing to unique features, including the occurrence of the so-called immune-related adverse events (irAEs). A multidisciplinary team, possibly including a cardio-oncology specialist, is warranted to achieve a favorable patient outcome. Cardiovascular toxicity, especially myocarditis, emerged as a life-threatening irAE in the real-word setting, and the European Society of Cardiology has recently published the first guideline on cardio-oncology to increase awareness and promote a standardized approach to tackle this complex multimodal issue, including diagnostic challenges, assessment, treatment, and surveillance of patients with cancer receiving ICIs. In this article, through a question & answer format made up of case vignettes, we offer a clinically oriented overview on the latest advancements of ICI-related cardiovascular toxicity, focusing on myocarditis and associated irAEs (myositis and myasthenia gravis within the so-called overlap syndrome), with the purpose of assisting clinicians and healthcare professionals in daily clinical practice

The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy

Background: An acceptable risk-benefit ratio may encourage the prescription of immune checkpoint inhibitors (ICI) near the late stage of life. The lung immune prognostic index (LIPI) was validated in advanced non-small cell lung cancer (NSCLC) patients treated with ICIs. The palliative prognostic (PaP) score without clinical prediction of survival (PaPwCPS) predicts early mortality probability in terminal cancer patients. Methods: We performed a retrospective study including 182 deceased advanced NSCLC patients, treated with single-agent ICI at our Institution. Two prognostic categories of high and low mortality risk were identified through ROC curve analysis for PaPwCPS and LIPI scores. Results: Most were >65 years of age (68.3%) and received second-line ICI (61.2%). A total of 29 (15.9%) and 131 (72.0%) patients died within 30 and 90 days from treatment start, respectively. A total of 81 patients (44.5%) received ICI during the last month of life. Baseline PaPwCPS and LIPI scores were assessable for 78 patients. The AUC of ROC curves was significantly increased for PaPwCPS as compared with LIPI score for both 30-day and 90-day mortality. A high PaPwCPS score was associated in multivariate analysis with increased 30-day (HR 2.69, p = 0.037) and 90-day (HR 4.01, p < 0.001) mortality risk. A high LIPI score was associated with increased 90-day mortality risk (p < 0.001). Conclusion: We found a tendency towards ICI prescription near the late stage of life. The PaPwCPS score was a reliable predictor of 30- and 90-day mortality

Promovendo a compreensão de textos em estudantes alfabetizados na infância e na idade adulta

Este estudo propõe uma análise e comparação do processo de compreensão de textos em alunos alfabetizados na idade adulta e alunos alfabetizados na infância. Participaram desta pesquisa 49 alunos adultos alfabetizados, do sexo masculino, com idade superior a 18 anos, frequentadores de instituições públicas ou privadas. Sendo que 29 universitários foram alfabetizados na infância (AC) e os outros 20 foram alunos alfabetizados na idade adulta (AA), sendo frequentadores do primeiro segmento do ensino fundamental, de classes de educação de jovens e adultos. Foram realizadas três etapas: no pré-teste, ambos os grupos, após a leitura de um texto, responderam um questionário e somente aqueles que obtiveram menos de 50% de acertos participaram da intervenção e do pós-teste. Na etapa da intervenção, os leitores menos habilidosos elaboraram um roteiro para a melhoria da compreensão de textos com a orientação do pesquisador. No pós-teste, esses mesmos participantes responderam um novo questionário, após a leitura de um novo texto. As comparações entre os resultados do pré e pós-teste mostraram que os leitores menos habilidosos melhoraram seus desempenhos nos níveis de compreensão textual, principalmente na macroestrutura e na argumentação

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes

The advent of immunotherapy and targeted therapies has dramatically changed the outcomes of patients affected by many malignancies. Pancreatic cancer (PC) remains one the few tumors that is not treated with new generation therapies, as chemotherapy still represents the only effective therapeutic strategy in advanced-stage disease. Agents aiming to reactivate the host immune system against cancer cells, such as those targeting immune checkpoints, failed to demonstrate significant activity, despite the success of these treatments in other tumors. In many cases, the proportion of patients who derived benefits in early-phase trials was too small and unpredictable to justify larger studies. The population of PC patients with high microsatellite instability/mismatch repair deficiency is currently the only population that may benefit from immunotherapy; nevertheless, the prevalence of these alterations is too low to determine a real change in the treatment scenario of this tumor. The reasons for the unsuccess of immunotherapy may lie in the extremely peculiar tumor microenvironment, including distinctive immune composition and cross talk between different cells. These unique features may also explain why the biomarkers commonly used to predict immunotherapy efficacy in other tumors seem to be useless in PC. In the current paper, we provide a comprehensive and up-to-date review of immunotherapy in PC, from the analysis of the tumor immune microenvironment to immune biomarkers and treatment outcomes, with the aim to highlight that simply transferring the knowledge acquired on immunotherapy in other tumors might not be a successful strategy in patients affected by PC

5G-crosshaul: an SDN/NFV integrated fronthaul/backhaul transport network architecture

This article proposes an innovative architecture design for a 5G transport solution (dubbed 5G-Crosshaul) targeting the integration of existing and new fronthaul and backhaul technologies and interfaces. At the heart of the proposed design lie an SDN/NFV-based management and orchestration entity (XCI), and an Ethernet-based packet forwarding entity (XFE) supporting various fronthaul and backhaul traffic QoS profiles. The XCI lever-ages widespread architectural frameworks for NFV (ETSI NFV) and SDN (Open Daylight and ONOS). It opens the 5G transport network as a service for innovative network applications on top (e.g., multi-tenancy, resource management), provisioning the required network and IT resources in a flexible, cost-effective, and abstract manner. The proposed design supports the concept of network slicing pushed by the industry for realizing a truly flexible, sharable, and cost-effective future 5G system.This work has been funded by the EU H2020 project “5G- Crosshaul: The 5G Integrated Fronthaul/Backhaul” (Grant no. 671598)

5G-Crosshaul: an SDN/NFV control and data plane architecture for the 5G integrated Fronthaul/Backhaul

This paper presents the control and data plane architecture design for a 5G transport solution (5G-Crosshaul) with the aim of integrating the fronthaul and backhaul network segments in a common transport stratum. The control plane relies on the Software-defined networking/Network Functions Virtualization concept to control and orchestrate the different elements of the network (the 5G-Crosshaul control infrastructure). The data plane is based on an mixed optical/packet-based forwarding entity (the 5G-Crosshaul forwarding element) that leverages the benefits of optical passthrough with the statistical multiplexing of packet-based transmission, working on top of a common frame format for both, fronthaul, and backhaul traffic (the 5G-Crosshaul common frame). In addition to the main architecture design, this work includes the impact of providing multi-tenancy support into the architecture of the overall system, in order to share the costs of building and operating the infrastructure among different operators. This architecture opens the 5G transport network as a service for innovative network applications on top (such as multi-tenancy, and resource management), provisioning the required network and IT resources in a flexible, cost-effective, and abstract manner. The proposed design supports the concept of network slicing pushed by the industry for realizing a truly flexible, sharable, and cost-effective future 5G system.This work has been funded by the EU H2020 project “5GCrosshaul: The 5G Integrated fronthaul/backhaul” (grant no. 671598)

miRNAs as candidate biomarker for the accurate detection of atypical endometrial hyperplasia/endometrial intraepithelial neoplasia

Endometrial cancer is the most common gynecologic malignancy in developed countries. Estrogen-dependent tumors (type I, endometrioid) account for 80% of cases and non-estrogen-dependent (type II, non-endometrioid) account for the rest. Endometrial cancer type I is generally thought to develop via precursor lesions along with the increasing accumulation of molecular genetic alterations. Endometrial hyperplasia with atypia/Endometrial Intraepithelial Neoplasia is the least common type of hyperplasia but it is the type most likely to progress to type I cancer, whereas endometrial hyperplasia without atypia rarely progresses to carcinoma. MicroRNAs are a class of small, non-coding, single-stranded RNAs that negatively regulate gene expression mainly binding to 3'-untranslated region of target mRNAs. In the current study, we identified a microRNAs signature (miR-205, miR-146a, miR-1260b) able to discriminate between atypical and typical endometrial hyperplasia in two independent cohorts of patients. The identification of molecular markers that can distinguish between these two distinct pathological conditions is considered to be highly useful for the clinical management of patients because hyperplasia with an atypical change is associated with a higher risk of developing cancer. We show that the combination of miR-205, -146a, and -1260b has the best predictive power in discriminating these two conditions (>90%). With the aim to find a biological role for these three microRNAs, we focused our attention on a common putative target involved in endometrial carcinogenesis: the oncosuppressor gene SMAD4. We showed that miRs-146a, -205, and-1260b directly target SMAD4 and their enforced expression induced proliferation and migration of Endometrioid Cancer derived cell lines, Hec1 a cells. These data suggest that microRNAs-mediated impairment of the TGF-beta pathway, due to inhibition of its effector molecule SMAD4, is a relevant molecular alteration in endometrial carcinoma development. Our findings show a potential diagnostic role of this microRNAs signature for the accurate diagnosis of Endometrial hyperplasia with atypia/Endometrial Intraepithelial Neoplasia and improve the understanding of their pivotal role in SMAD4 regulation

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating KRAS mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is the most common KRAS alteration. Although KRAS mutations have been considered undruggable for over 40 years, the recent discovery of allelic-specific KRAS inhibitors has paved the way to personalized cancer medicine for patients with tumours harbouring these mutations. Here, we review the current treatment landscape for patients with advanced NSCLCs harbouring a KRAS G12C mutation, including PD-(L) 1-based therapies and direct KRAS inhibitors as well as sequential treatment options. We also explore the possible mechanisms of resistance to KRAS inhibition and strategies to overcome resistance in patients with KRAS G12C-mutant NSCLC